These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28056913)

  • 1. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
    Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
    BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.
    Li J; Wu MF; Lu HW; Chen Q; Lin ZQ; Wang LJ
    Cancer Med; 2016 Aug; 5(8):1863-72. PubMed ID: 27350066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.
    Kieler M; Unseld M; Wojta J; Kaider A; Bianconi D; Demyanets S; Prager GW
    Med Oncol; 2018 Nov; 36(1):1. PubMed ID: 30426271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
    Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
    Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma.
    Ji F; Fu SJ; Guo ZY; Pang H; Ju WQ; Wang DP; Hua YP; He XS
    Medicine (Baltimore); 2016 Jul; 95(27):e4065. PubMed ID: 27399091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer.
    Xiao Y; Yang H; Lu J; Li D; Xu C; Risch HA
    BMC Cancer; 2019 Oct; 19(1):1020. PubMed ID: 31664937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
    Lembeck AL; Posch F; Klocker EV; Szkandera J; Schlick K; Stojakovic T; Kornprat P; Lackner C; Gerger A; Stoeger H; Stotz M; Pichler M
    Clin Chem Lab Med; 2019 Apr; 57(5):740-744. PubMed ID: 30307891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
    Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
    Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varying postresection lactate dehydrogenase with overall survival of early stage pancreatic cancer patients: A retrospective study.
    Xiao Y; Xie Z; Shao Z; Chen W; Xie H; Qin G; Zhao N
    Medicine (Baltimore); 2017 Mar; 96(12):e6399. PubMed ID: 28328834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma.
    Nissen NI; Kehlet S; Johansen AZ; Chen IM; Karsdal M; Johansen JS; Diab HMH; Jørgensen LN; Sun S; Manon-Jensen T; He Y; Langholm L; Willumsen N
    Int J Cancer; 2021 Jul; 149(1):228-238. PubMed ID: 33687786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
    Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.